Treatment of metastatic and recurrent cervix cancer with chemotherapy: A randomised trial comparing hydroxyurea with cisdiamminedichloro‐platinum plus methotrexate

Abstract

In a randomised trial comparing single-agent chemotherapy (hydroxyurea) to combination chemotherapy in advanced cervix cancer, response was seen in 57% (including 13% CR) of patients receiving the combination (DDP + MTX) regimen. Responding patients survived significantly longer (11 months) than either those receiving hydroxyurea or those not responding to combination chemotherapy (4 months). Two patients remain in complete remission for 14+ and 17+ months.